Novartis | NVS - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
AbbVie USD 12.59B 180M 2025-12
Amgen USD 9.14B 432M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
Bausch Health Companies USD 2.19B 160M 2026-03
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Canopy Growth CAD 140.42M 113.56M 2025-12
Corcept Therapeutics USD 39.07M 20.71M 2026-03
Drreddys Laboratories INR 1.41B 11.6M 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
Gilead Sciences USD 4.91B 182M 2025-12
GlaxoSmithKline GBP 7.94B 178M 2026-03
Glaxosmithkline GBP 10.45B 707.81M 2025-12
J&J USD 21.33B 3.72B 2025-12
Merck USD 11.78B 345M 2025-12
Novartis USD 9.6B 2.69B 2026-03
Novartis USD 12.29B 3.3B 2025-12
Pacira USD 125.64M 1.57M 2026-03
Perrigo USD 612.8M 31.6M 2025-12
Pfizer USD 15.84B 2.27B 2025-12
Phibro Animal Health USD 215.87M 2.02M 2025-12
Prestige Brands USD 190.46M 8.54M 2025-12
Roche Holding CHF 11.9B 460M 2025-12
Sanofi EUR 482M 85M 2026-03
Sanofi EUR 397M 186.13M 2025-12
Supernus Pharmaceuticals USD 187.8M 16.55M 2025-12
Zoetis USD 1.59B 49M 2025-12